Catalyst Wealth Management’s AbbVie ABBV Stock Holding History

Catalyst Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,341	Closed	-$378K	–	121
2022 Q4	$378K	Buy	+2,341	New	+$359K	0.36%	89

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Catalyst Wealth Management's ABBV Position: Q1 2023 in Review

Catalyst Wealth Management sold out of AbbVie (ABBV) in Q1 2023, closing a stake of 2,341 shares — an estimated $378K sold.

Catalyst Wealth Management first reported a position in ABBV in Q4 2022 and held it in 1 quarter. The position peaked at $378K in Q4 2022. 3,141 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

Catalyst Wealth Management reported no remaining AbbVie position as of Q1 2023 after selling out during the quarter.
Catalyst Wealth Management sold 2,341 AbbVie shares in Q1 2023, an estimated $378K.
Catalyst Wealth Management first reported a position in AbbVie in Q4 2022 and held it in 1 quarter.
Catalyst Wealth Management's AbbVie position peaked at $378K in Q4 2022.
3,141 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on Catalyst Wealth Management's 13F filing for Q1 2023, filed 11 Apr 2023.